Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average recommendation of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $6.63.

Several research analysts recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, February 27th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after buying an additional 11,390 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Taysha Gene Therapies by 23.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares during the period. Wellington Management Group LLP bought a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $931,000. Barclays PLC increased its stake in shares of Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after acquiring an additional 193,046 shares during the last quarter. Finally, State Street Corp raised its position in shares of Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after acquiring an additional 150,647 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $1.20 on Friday. The company’s fifty day moving average is $1.60 and its two-hundred day moving average is $1.85. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $4.32. The stock has a market capitalization of $246.00 million, a P/E ratio of 1.90 and a beta of 0.96. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. On average, sell-side analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.